B. Metzler seel. Sohn & Co. AG Cuts Position in Moderna, Inc. (NASDAQ:MRNA)

B. Metzler seel. Sohn & Co. AG lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 32.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 15,267 shares of the company’s stock after selling 7,406 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Moderna were worth $635,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRNA. Alliancebernstein L.P. increased its position in shares of Moderna by 0.5% in the fourth quarter. Alliancebernstein L.P. now owns 331,439 shares of the company’s stock valued at $13,781,000 after buying an additional 1,705 shares in the last quarter. AIA Group Ltd grew its stake in Moderna by 192.4% in the 4th quarter. AIA Group Ltd now owns 47,640 shares of the company’s stock valued at $1,981,000 after acquiring an additional 31,349 shares during the last quarter. CIBC Private Wealth Group LLC increased its holdings in Moderna by 73.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 7,046 shares of the company’s stock valued at $304,000 after acquiring an additional 2,979 shares in the last quarter. Allianz SE acquired a new position in Moderna during the fourth quarter worth about $151,000. Finally, Aufman Associates Inc lifted its holdings in shares of Moderna by 26.2% in the fourth quarter. Aufman Associates Inc now owns 11,066 shares of the company’s stock valued at $460,000 after purchasing an additional 2,299 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Price Performance

Moderna stock opened at $25.11 on Friday. The firm’s fifty day moving average price is $33.55 and its 200 day moving average price is $43.01. The company has a market capitalization of $9.71 billion, a price-to-earnings ratio of -2.71 and a beta of 2.23. Moderna, Inc. has a 12-month low of $23.76 and a 12-month high of $170.47.

Analyst Ratings Changes

MRNA has been the subject of a number of recent research reports. Morgan Stanley dropped their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Evercore ISI set a $50.00 price target on Moderna in a research report on Friday, February 14th. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Bank of America dropped their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a report on Tuesday, February 18th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $59.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.